-
-
-
-
-
-
-
Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA
-
-
-
-
-
-
-
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hype
-
-
-
-
-
-
-
Bristol Myers Squibb partners with Anthropic to deploy AI across operations
-
-
-
-
-
-
-
Bristol Myers Squibb and Pfizer partner with Mark Cuban's Cost Plus Drugs
-
-
-
-
-
-
-
Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride)
-
-
-
-
-
-
-
FDA approves Bristol Myers Squibb's Sotyktu for psoriatic arthritis
-
-
-
-
-
-
-
Barclays launches U.S. biopharma coverage with four preferred picks
-
1,212,257 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

